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Background: The rate of catastrophic musculoskeletal injuries (CMI) in racehorses is
high in the United States compared to other countries. Fewmodifiable risk factors related
to lameness, medication, and surgery history have been identified.
Objective: To detect management factors that increase risk of CMI by comparing
medical histories between horses that sustained, and horses that did not sustain, a CMI.
Study design: Case-control.
Methods: Racehorse necropsy data (May 2012-June 2013) were obtained through
the California Horse Racing Board Postmortem Program. Attending veterinarians of
Thoroughbreds (TB) and Quarter Horses (QH) that experienced CMI, and of three
matched control horses, were invited to complete an online veterinary medical history
survey. We investigated associations between CMI and lameness, medication, surgery,
and exercise history using multivariable logistic regression.
Results: There were 146 TB (45 cases, 101 controls) and 17 QH (11 cases, 6 controls)
surveys completed. TB cases were more likely to show signs of lameness within the 3
months prior to death compared to controls. A high proportion of both cases (64.3%)
and controls (76.8%) were administered medications, but unraced TB case horses were
more likely to have been administered systemic medications compared to those that
previously raced. TB cases were more likely to have raced with greater intensity during
their career, but had eased off in themonth preceding CMI. For QHs, there was insufficient
power to detect significant differences between cases and controls that showed signs
of lameness, or that were administered medications. Surgery history was not associated
with CMI.
Main limitation: Insufficient power to detect small effect sizes.
Conclusions: The study provides information that can be used to aid in identification of
horses at high risk for catastrophic injury, and management factors that can be modified
to reduce the risk for all horses.
Keywords: epidemiology, musculoskeletal injury, horse, equine, fatality
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INTRODUCTION
Musculoskeletal injuries are the primary cause of death for
racehorses (1–4), and in California, there are about two
catastrophic musculoskeletal injuries (CMI) for every 1,000 race
starts in both Thoroughbred (TB) (5–7), and Quarter Horse
(QH) racing (3, 7). This incidence of CMI is higher than the
incidence reported in other countries such as Australia and New
Zealand (0.4/1,000 starts) [(2, 8)], and the United Kingdom
(0.7/1,000 starts) (4). California has seen a reduction in the
frequency of fatalities in recent years (9), with this reduction
credited to the implementation of a Racing Safety Program
that has included horseshoe restrictions, improvement of
track surfaces, restrictions on injection of some medications
(e.g., corticosteroids), and continuing education of trainers.
Implementation of other factors related to the management of
the horse should therefore also influence the incidence of such
injuries.
Risk factors investigated for CMI in racehorses have been
well reviewed (10–16). Factors associated with increased risk
of CMI or fatality include horse and race-level characteristics
such as horse age (4, 17–23), age at first start (21–23), horse
sex (17, 19, 22, 24, 25), race distance (21–24, 26), type and
condition of track surface (4, 20–24, 27–30), class of race (18,
22, 24), and number of race starters (18). Factors related to
management or training and racing programs that are associated
with CMI include prior racing history (21, 22, 25, 31–33), horse
shoe characteristics (e.g., use of toe grabs) (25, 34), and lay-
up history or extended intervals since last race (24, 25, 32).
Additionally, musculoskeletal injury has been reported to be
associated with abnormal prerace physical inspection findings
(26, 35), previous number of injuries, being scratched or having
been on the vet list (23), and with administration of non-steroidal
anti-inflammatory drugs (NSAIDS) or corticosteroids (36, 37).
Despite this long list of risk factors, factors related to history of
lameness, administration of all types of medication, and surgery
have yet to be identified.
To obtain information on these factors, attending
veterinarians of horses that experienced a CMI, and of
control horses (horses that competed in the same race or trained
on the same day as their respective case but did not have a
fatal injury), were invited to complete an online veterinary
medical history survey. The aim of this survey was to identify
information that can be used to aid in identification of horses at
risk of catastrophic injury, and management factors that can be
modified to reduce this risk in racehorses.
METHODS
Study Population
The target population were attending veterinarians of TB and
QH racehorses that experienced a CMI during racing or training
(case) and of three matched control horses, in California between
May 1, 2012 and June 30, 2013.
Case horses were racehorses that were necropsied through
the California Animal Health and Food Safety Laboratory
System (CAHFS) for the California Horse Racing Board
(CHRB) Postmortem Program. CAHFS conduct post-mortem
examinations of every horse that has died or was euthanized
at racing or training facilities under the jurisdiction of the
CHRB. Three control racehorses were selected for each case. For
cases that died as a result of an injury incurred during racing,
controls were selected from unaffected horses that competed in
the same race. For cases that died as a result of an injury incurred
during training, controls were selected from unaffected horses
that recorded an official timed workout on the same day and
at the same racetrack as their respective case, and matched on
breed, age (years), and sex (intact male, neutered male, female).
Career race and officially timed workout reports for each case
and control horse were obtained from a commercial database of
official racing industry records (InCompass Solutions Inc., The
Jockey Club, Lexington, KY, USA). From these records, high-
speed exercise history variables were generated using custom
software detailed elsewhere (38, 39). Data were limited to high-
speed exercise performed to the date of death of the respective
case and included variables associated with their career (from
the first recorded event to death), including number of events
(races and official timed works), time between events, intensity of
events, and lay-up (≥60 days without an official recorded event).
Survey
A three-part 48-question confidential online survey was designed
in the open source software LimeSurvey (Supplementary File 1;
LimeSurvey 2.0, 2013; www.limesurvey.org). The survey was
piloted by official veterinarians prior to study commencement.
Consent was obtained from the attending veterinarian (having
the owners’ authority to act as agents for the owner in relation
to veterinary matters). The information was maintained in
confidence under the relevant law, including, but not limited
to, the “official information privilege” (California Evidence Code
section 1040) and the “veterinary services privilege” (California
Business and Professions Code section 4857). Closed-ended
multiple-choice and categorical questions were primarily used
in the three sections: lameness history, medication history, and
surgery history. Open-ended text fields were included at the end
of each section to obtain more detailed information.
The attending veterinarians of the case and control racehorses
were invited to voluntarily complete the online veterinary
medical history survey. The individual survey links were
distributed via email to the California Horse Racing Board
official veterinarians, who forwarded the email on to the relevant
attending veterinarian of each racehorse. Reminders were issued
by email to participants that did not respond within one month
of the date of death of the case horse. The mean time taken to
complete a survey, from opening the online survey to submitting
the survey, was 7.4 (standard deviation 7.6) minutes.
Statistical Analysis
Survey responses were compared between cases and controls,
stratified by racehorse breed. Logistic regression was used to
assess differences between groups for the whole dataset for
lameness, medication administration, and surgery history, as
well as between TB cases and controls for exercise history
variables. Because there were only 31 cases with complete
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matching to controls (21 cases with one matched control,
eight cases with two matched controls, and two cases with
three matched controls), we fitted univariable logistic regression
models, adjusting for clustering of random-effects on the variable
indicating matched cases and controls (i.e., matched set id). This
method avoided substantial data loss. To ensure our findings
held up to this method we also fitted the subset of matched
data using univariable conditional logistic regression models.
Where a number in a 2 × 2 contingency table cell was <10,
univariable exact logistic regression was employed. Cases or
controls were omitted from analysis of specific medications
where the attending veterinarian noted that it was unknown
whether administration of medication had taken place while
under their care or otherwise. Study factors in univariable
analysis that were p < 0.20 were entered into a multivariable
logistic regression model, adjusting for clustering of matched
cases and controls, and omitted in a backwards stepwise
manner. Variables were retained in the model if p < 0.05 or
if they modified the coefficients of other covariates by more
than 10%. For continuous variables, violation of the linearity
assumption in the logit was assessed for each of the study factors
using the Box-Tidwell transformation test. Two-way interaction
terms between biologically plausible study factors were assessed.
Model diagnostics of the final model included the Hosmer-
Lemeshow’s goodness-of-fit test, the link test to identify model
specification error, examination of tolerance (>0.1), and the
variance inflation factor (VIF < 10). A p ≤ 0.05 was considered
statistically significant for all tests. Odds ratios (OR) and their
95% confidence intervals (95% CI) are presented. All statistical
analyses were conducted using Stata, version 14.2 (StataCorp,
College Station, Tex, USA).
RESULTS
Of the 660 surveys distributed to veterinarians of cases (n= 165)
and controls (n = 495), 31.8% (n = 210) of surveys were
initiated, and 29.2% (n = 193) were completed in their
entirety. The 17 unusable survey responses were incomplete
or were from veterinarians that indicated that they were not
the primary attending veterinarian for that horse. Of the 193
complete surveys, 84.5% (n = 163) were completed by attending
veterinarians of cases that died due to a CMI or their respective
controls in association with training, racing, or non-exercise. The
remaining 30 surveys were non-musculoskeletal cases (n = 4)
and controls matched to non-musculoskeletal cases (n = 26)
that were removed from analysis. Nine surveys (three cases,
six controls) were completed for TB racehorses that died as a
result of an injury incurred when not exercising. The three cases
included skull fracture as a result of a severe procaine reaction,
proximal phalangeal fracture of unknown cause, and a case of
chronic laminitis. Of the CMI cases and controls, 33.9% (56/165)
responses were from the attending veterinarian of a case horse,
and 21.6% (107/495) were from the attending veterinarian of
control horses. Only CMI cases, and respective controls that died
associated with exercise, have been included in the following
results.
The attending veterinarians were asked how long the horse
was under their care: 9.2% (n = 15/163) of horses were under
the veterinarians care for <1 month, 36.2% (n = 59/163) for
1–6 months, 21.5% (n = 35/163) for 6–12 months, and 33.1%
(n = 54/163) for more than 12 months. There were 146 surveys
(45 cases, 101 controls) completed for Thoroughbreds and 17
surveys completed for Quarter Horses (11 cases, 6 controls).
Racing or Training
For TBs, 72 (25 cases, 47 controls) of the surveys were related
to a CMI incurred by the case during racing, and 65 (17 cases,
48 controls) were related to a CMI incurred by the case during
training. For QHs, all 17 (11 cases, 6 controls) of the surveys were
related to a CMI incurred by the case during racing.
In the free text notes, 24.0% (6/25) of the attending
veterinarians of cases and 14.9% (7/47) of controls in the TB
racing sample; 17.6% (3/17) of cases and 2.1% (1/48) of controls
in the TB training sample; and 0% (0/11) of the cases and 16.7%
(1/6) of the controls in the QH racing sample, noted that the
reason for missing or unknown information was that the horse
had been claimed, shipped in, or changed trainers in the previous
12 months.
Lameness
For both TBs and QHs there were no significant differences
between cases and controls in proportion of lameness observed,
although 37.8% (14/37) TB cases were lame in the 0–3 months
prior to CMI compared to 23.3% (21/90) of controls (p = 0.115)
(Tables 1, 2).
In the conditional logistic regression model using only the
subset of matched cases and controls, cases had 4.34 (n = 58;
95% CI 1.16, 16.26; p = 0.029) greater odds of showing signs of
lameness at any time compared to their matched controls, most
evident for TB cases that showed signs of lameness within the
three months prior to death. The matched subset of TB cases
that died during training had 5.67 (n = 37; 95% CI 1.16, 27.70;
p = 0.032) greater odds of being lame at any time compared to
their matched controls; again, most evident for TB training cases
that showed signs of lameness within the three months prior to
death.
Most poor performance or lameness problems were localized
to the forelimb (Supplementary Table 1). There was no
significant difference in proportion of cases or controls with
either hindlimb or forelimb lameness’ (p = 0.705). For TB
cases, 47.6% (10/21) were localized to a bone, 52.4% (11/21) to
a joint, 19.0% (4/21) to a tendon or ligament, and one was a
severe laceration (two cases had multiple affected structures).
For TB controls, 47.7% (21/44) were localized to a bone, 34.1%
(15/44) to a joint, 13.6% (6/44) to a tendon or ligament, 2.3%
(1/44) to a muscle, and one each being a hoof abscess and
greater trochanteric bursa (three cases had multiple affected
structures). For QH cases that had lameness problems localized
to a structure, both cases had multiple affected structures with
100% (2/2) localized to both a bone and to a joint, tendon, or
ligament. For QH controls, 100% (2/2) were localized to a joint.
A definitive diagnosis for lameness was reached for 47.6%
(10/21) of the lame TB cases and 68.2% (30/44) of the lame TB
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TABLE 1 | Associations from univariable logistic regression models, adjusting for
matching of cases and controls, between catastrophic musculoskeletal injury
sustained during racing or training and lameness, medication and surgery
histories of Thoroughbred racehorses in California, 2012–2013.
Cases
(n = 42)
Controls
(n = 95)
Odds ratio
(95% CI)
p-value
Yes No Yes No
Lameness
0–3 months 14 23 21 69 2.00 (0.84, 4.74) 0.115
3–6 months 4 27 14 62 0.66 (0.14, 2.36) 0.702
6–12 months 7 12 22 41 1.09 (0.31, 3.52) 1.000
>12 months 5 7 10 36 2.52 (0.52, 11.79) 0.301
Anytime* 21 16 44 48 1.43 (0.65, 3.13) 0.368
IA or IT
medications/injections
20 22 46 49 0.97 (0.47, 2.00) 0.931
Joint block
Previous week 1 27 2 58 1.07 (0.02, 21.46) 1.000
Previous month 2 26 4 56 1.08 (0.09, 8.07) 1.000
>1 month 4 24 9 51 0.95 (0.19, 3.82) 1.000
Anytime 5 23 10 50 1.09 (0.26, 3.99) 1.000
Corticosteroids
Previous week 4 26 8 64 1.23 (0.25, 5.08) 0.986
Previous month 8 22 20 52 0.95 (0.31, 2.68) 1.000
>1 month 9 21 19 53 1.19 (0.41, 3.33) 0.886
Anytime 15 15 28 44 1.57 (0.70, 3.54) 0.276
PSGAGS
Previous week 5 19 15 46 0.81 (0.20, 2.79) 0.952
Previous month 6 18 17 44 0.86 (0.24, 2.79) 1.000
>1 month 3 21 13 48 0.53 (0.09, 2.23) 0.544
Anytime 18 6 19 42 0.74 (0.21, 2.36) 0.780
Hyaluronic acid (ha)
Previous week 2 25 2 57 2.26 (0.16, 32.76) 0.745
Previous month 4 23 6 53 1.53 (0.29, 7.17) 0.770
>1 month 4 23 7 52 1.29 (0.25, 5.68) 0.948
Anytime 8 19 9 50 2.31 (0.67, 7.93) 0.210
IRAP
Previous week 0 21 0 49 – –
Previous month 0 21 0 49 – –
>1 month 1 20 0 49 2.33 (0.06, +Inf) 0.600
Anytime 1 20 0 49 2.33 (0.06, +Inf) 0.600
Antibiotics
Previous week 1 21 1 50 2.35 (0.03, 190.56) 1.000
Previous month 1 21 1 50 2.35 (0.03, 190.56) 1.000
>1 month 4 18 8 43 1.19 (0.23, 5.17) 1.000
Anytime 4 18 8 43 1.19 (0.23, 5.17) 1.000
Stem cells
Previous week 0 21 1 47 2.29 (0.00, 89.14) 1.000
Previous month 0 21 1 47 2.29 (0.00, 89.14) 1.000
>1 month 0 21 0 48 – –
Anytime 0 21 1 47 2.29 (0.00, 89.14) 1.000
Systemic medications 25 17 70 25 0.53 (0.24, 1.13) 0.100
Phenylbutazone (bute)
Previous week 16 13 48 33 0.85 (0.37, 1.93) 0.691
(Continued)
TABLE 1 | Continued
Cases
(n = 42)
Controls
(n = 95)
Odds ratio
(95% CI)
p-value
Yes No Yes No
Previous month 21 8 59 22 0.98 (0.44, 2.18) 0.958
>1 month 10 19 31 50 0.85 (0.35, 2.04) 0.714
Anytime 22 7 61 20 1.03 (0.35, 3.29) 1.000
Flunixin
Previous week 9 13 23 39 1.17 (0.38, 3.52) 0.944
Previous month 11 11 34 28 0.82 (0.32, 2.11) 0.685
>1 month 4 18 21 41 0.44 (0.10, 1.57) 0.264
Anytime 12 10 35 27 0.93 (0.36, 2.35) 0.871
Ketoprofen
Previous week 6 12 10 38 1.88 (0.46, 7.27) 0.457
Previous month 7 11 15 33 1.39 (0.38, 4.91) 0.760
>1 month 1 17 5 43 0.51 (0.01, 5.07) 0.949
Anytime 8 10 17 31 1.45 (0.41, 5.01) 0.692
Methocarbamol
Previous week 5 13 12 41 1.31 (0.30, 5.01) 0.882
Previous month 6 12 19 34 0.90 (0.24, 3.11) 1.000
>1 month 2 16 17 36 0.27 (0.03, 1.36) 0.144
Anytime 6 12 22 31 0.71 (0.19, 2.43) 0.746
bute + flunixin 23 7 63 20 1.04 (0.36, 3.31) 1.000
bute + flunixin +
ketoprofen
23 7 63 20 1.04 (0.36, 3.31) 1.000
psgags + ha 12 16 23 43 1.40 (0.57, 3.43) 0.459
steroids + psgags 19 12 36 38 1.67 (0.75, 3.70) 0.205
steroids + ha 15 16 29 44 1.42 (0.64, 3.15) 0.386
steroids + psgags + ha 19 13 37 38 1.50 (0.69, 3.25) 0.303
Total medications 27 15 73 22 0.54 (0.24, 1.25) 0.151
Tendon/ligament injections 3 39 6 89 1.14 (0.18, 5.67) 1.000
Diagnostic block 1 23 5 61 0.53 (0.01, 5.15) 0.981
Platelet rich plasma 0 24 0 62 – –
IRAP 0 24 0 62 – –
Stem cells 0 24 0 62 – –
Other 2 24 1 53 4.33 (0.22, 265.36) 0.491
Surgeries 3 27 7 78 1.24 (0.19, 5.90) 1.000
Orthopaedic 3 27 1 78 8.46 (0.65, 460.60) 0.125
Non-orthopaedic 1 27 6 78 0.48 (0.01, 4.28) 0.878
Reference category for interpretation of the Odds Ratio is absence of lameness,
medication, or surgery. *Anytime represents a positive answer to at least one of 0–3,
3–6, 6–12, or > 12 months; or previous week, previous month, or > 1 month categories.
Where at least one cell contains a value <10, exact logistic regression odds ratios and
p-values have been reported. Medications note: Other systemic medications reported
include: Furosemide, DMSO, Osteoform, Vetalog, Ventipulmin, Tranq, Ace, Gastroguard.
controls, and 50.0% (1/2) of the lameQH cases and 50.0% (1/2) of
the lame QH controls. Procedures used to diagnose the condition
included clinical evaluation (TB n = 18), diagnostic analgesia
(TB n = 7), radiography (TB n = 19), nuclear scintigraphy
(TB n = 5), and ultrasonography (TB n = 1). Other diagnostic
procedures included blood work and alkaline phosphatase test.
No procedures or treatments were reported for the QHs that
showed signs of poor performance or lameness.
Of the TBs, 85.7% (18/21) cases and 97.7% (43/44)
controls were treated for their diagnosed condition
including: 66.7% (14/21) cases and 52.3% (23/44) controls
Frontiers in Veterinary Science | www.frontiersin.org 4 September 2018 | Volume 5 | Article 217
Hitchens et al. Predictors of Racehorse Catastrophic Injury
TABLE 2 | Associations from univariable exact logistic regression models between
catastrophic musculoskeletal injury sustained during racing and lameness,
medication and surgery histories of Quarter Horses in California, 2012–2013.
Cases
(n= 11)
Controls
(n = 6)
Odds ratio
(95% CI)
p-value
Yes No Yes No
Lameness
0–3 months 2 8 2 4 0.52 (0.03, 9.78) 0.604
3–6 months 0 7 1 5 0.86 (0.00, 33.43) 0.462
6–12 months 1 4 0 5 1.00 (0.03, +Inf) 1.000
>12 months 0 2 0 3 – –
Anytime* 2 8 2 4 0.52 (0.03, 9.78) 0.604
IA or IT medications 7 4 5 1 0.37 (0.01, 5.52) 0.600
Joint block 0 6 1 3 0.67 (0.00, 26.00) 0.400
Corticosteriods 7 3 5 1 0.49 (0.01, 8.45) 1.000
PSGAGS 2 6 1 2 0.69 (0.02, 58.78) 1.000
Hyaluronic acid 1 6 2 1 0.12 (0.00, 4.05) 0.183
IRAP 0 6 0 3 – –
Antibiotics 1 6 0 1 0.43 (0.01, +Inf) 1.000
Stem cells 0 6 0 3 –
Systemic medications 8 3 6 0 0.41 (0.00, 4.43) 0.515
Phenylbutazone 7 2 5 1 0.72 (0.01, 17.65) 1.000
Flunixin 5 2 4 0 0.66 (0.00, 9.58) 0.491
Ketoprofen 6 2 3 1 2.00 (0.01, 27.88) 1.000
Methocarbamol 0 3 0 2 – –
Tendon/ligament
injections
0 11 0 6 – –
Total medications 8 3 6 0 0.41 (0.00, 4.43) 0.515
Surgeries 1 6 0 3 0.43 (0.01, +Inf) 1.000
Reference category for interpretation of the Odds Ratio is absence of lameness,
medication, or surgery. *Anytime represents a positive answer to at least one of 0–3,
3–6, 6–12, or > 12 months. Due to the low numbers, time of medication administration
was not stratified as per Table 1.
administered medications, 4.8% (1/21) cases and 4.5% (2/44)
controls underwent surgery, 0% (0/21) cases and 13.6% (6/44)
controls underwent ESWT (shockwave), 4.8% (1/21) cases and
11.4% (5/44) controls underwent physical therapy, and 52.4%
(11/21) cases and 43.2% (19/44) controls were sent to layup.
For both cases and controls, percentage of career in layup was
associated with an increased likelihood of lameness at any time
(OR 1.02; 95% 1.01, 1.03; p = 0.024) compared to TBs that were
not lame. Non-lame TBs had a mean of 19.2% (±21.9%) of their
career in layup compared to lame TBs with 30.2% (±25.7%). To
assess whether information on lay-up given in the survey agreed
with information obtained from the horse’s high-speed exercise
history we conducted logistic regression with indication of layup
in the survey as the outcome. Indication of layup in the survey
was associated with greater mean weeks in layup (OR 1.03; 95%
CI 1.01, 1.06; p = 0.009) and a greater percentage of their career
in layup (OR 1.03; 95% 1.01, 1.05; p < 0.001), derived from the
career race and officially timed workout reports.
Of the TBs treated for poor performance or lameness, 42.9%
(9/21) of cases and 54.5% (24/44) of controls remained in training
with no disruption (p = 0.538), 28.6% (6/21) of cases and 43.2%
(19/44) of controls returned to racing and performed as they had
previously (p = 0.392), and 4.8% (1/21) of cases and 9.1% (4/44)
controls returned to racing with worse performance (p = 0.953).
This question did not apply to horses that were not lame at any
time.
Medication
There was no significant difference in proportions between
TB cases and controls administered any medication, with
64.3% (27/42) of cases and 76.8% (73/95) of controls being
administered any medication: 47.6% (20/42) of cases and 48.4%
(46/95) of controls administered intra-articular or intrathecal
injections, 59.5% (25/42) of cases and 73.7% (70/95) of controls
administered systemic medication, and 7.1% (3/42) of cases
and 6.3% (6/95) of controls administered tendon or ligament
injections.
There were no significant differences between TB cases and
controls administered specific medications, with the exception
that TB training-related cases (38.5% or 5/13) were more
likely to have been administered hyaluronic acid injections
compared to controls (10.0% or 3/30) (OR 5.63; 95% CI 1.05,
30.26; p = 0.044). The effect of combinations of medications
were also investigated for phenylbutazone (bute) and flunixin;
bute, flunixin, and ketoprofen; polysulfated glycosaminoglycan
(PSGAGs) and hyaluronic acid (HA); corticosteroids and
PSGAGs; corticosteroids and HA; and corticosteroids, PSGAGs
and HA. TB cases were found to have greater odds of being
administered these combinations of medications compared to
controls, but these results did not reach statistical significance
(Table 1).
No significant difference in proportions of QH cases and
controls that were administered medication was found, with
72.7% (8/11) of cases and 100% (6/6) of controls being
administered any medication: 63.6% (7/11) of cases and 83.3%
(5/6) of controls administered intra-articular or intrathecal
injection, 72.7% (8/11) of cases and 100% (6/6) of controls
administered systemic medication, and none of the cases or
controls administered tendon or ligament injection (Table 2).
Surgery
Eleven racehorses had a reported surgery (TB three cases,
seven controls; QH one case). No significant difference
was found in proportions between TB or QH cases and
controls that underwent surgery, though a greater proportion
of TB cases had orthopedic surgery compared to controls
(Tables 1, 2).
Three TB cases had orthopedic fixation surgery within 12
months prior to death (two screw fixations, one both screw and
plate fixation). These cases also had one tie back surgery, and two
arthroscopies. One TB control underwent proximal phalangeal
fragment removal; the other six TB controls underwent primarily
non-orthopedic surgeries (two castrations, colic surgery, caslick,
eye enucleation, and sequestrum removal). The one QH case
underwent orthopedic surgery involving both screw and plate
fixation to right shoulder, and non-orthopedic soft tissue surgery
0–3 months prior to death.
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TABLE 3 | Associations from univariable logistic regression models, adjusting for matching of cases and controls, between catastrophic musculoskeletal injury and
exercise history variables for Thoroughbred racehorses in California, 2012–2013.
Cases (n = 42) Controls (n = 95) Odds ratio
(95% CI)
p-value
n Median (IQR) n Median (IQR)
Horse age (d) 42 1410 (1133, 1770) 95 1375 (1119, 1729) 1.00 (1.00, 1.00) 0.398
Horse sex
Male gelding 14 – 37 – Reference
Male entire 13 – 22 – 1.56 (0.69, 3.53) 0.285
Female 15 – 36 – 1.10 (0.55, 2.20) 0.785
Career
Raced
Previously raced 35 – 79 – Reference
Unraced 7 – 16 – 0.99 (0.42, 2.32) 0.977
Races (No.) 42 11 (4, 17) 95 6 (2, 13) 1.41 (1.09, 1.83)a 0.010
Works (No.) 42 27 (16, 43) 95 24 (13, 43) 1.08 (0.84, 1.39)a 0.555
Events (No.) 42 39.5 (23, 63) 95 29 (15, 56) 1.13 (0.89, 1.45)a 0.313
Race distance (f) 42 63.25 (26.5, 111.5) 95 39.5 (9, 84.5) 1.31 (1.03, 1.68) 0.029
Work distance (f) 42 111.5 (69, 172) 95 101 (51, 188) 1.05 (0.84, 1.32) 0.640
Total (event) distance (f) 42 174.75 (105.5, 318.5) 95 139 (65, 267) 1.09 (0.89, 1.35) 0.407
Mean race distance (f) 35 6.13 (5.43, 6.70) 79 6.50 (5.75, 7.45) 0.73 (0.51, 1.04) 0.077
Mean work distance (f) 41 4.14 (3.80, 4.33) 95 4.18 (3.71, 4.47) 0.89 (0.52, 1.50) 0.652
Mean event distance (f) 41 4.67 (4.29, 4.88) 95 4.67 (4.00, 5.03) 0.92 (0.65, 1.31) 0.657
Career length (d) 42 532 (212, 876) 95 487 (192, 808) 1.14 (0.93, 1.40) 0.218
Active career length (d) 42 425 (170, 678) 95 117 (301, 531) 1.15 (0.92, 1.44)a 0.212
Layup
Number of layups 42 1 (0, 2) 95 1 (0, 2) 1.06 (0.72, 1.56) 0.756
Total layup time (d) 42 144 (0, 317) 95 130 (0, 277) 1.00 (1.00, 1.00) 0.801
Mean layup time (d) 42 125.5 (0, 187.5) 95 114 (0, 185) 1.00 (1.00, 1.00) 0.745
Percentage of career in layup 42 26.51 (0, 37.54) 95 23.27 (0, 40.41) 1.00 (0.98, 1.01) 0.811
Time since last layup (d) 42 194.5 (116, 372) 95 136 (75, 232) 1.22 (0.96, 1.54)a 0.102
Events since last layup (No.) 42 22 (14, 37) 95 15 (10, 26) 1.01 (0.99, 1.02) 0.236
Rate
Career
Races per year 42 6.15 (4.23, 9.82) 95 4.93 (2.25, 8.51) 2.03 (1.25, 3.31)a 0.004
Works per year 42 17.96 (13.11, 33.57) 95 23.69 (7.46, 32.68) 0.76 (0.51, 1.12)a 0.161
Events per year 42 26.06 (19.71, 41.48) 95 29.58 (23.79, 40.56) 0.79 (0.50, 1.25)a 0.314
Distance raced (f/mo) 42 3.12 (2.25, 5.09) 95 2.39 (1.19, 4.33) 1.10 (0.96, 1.27) 0.167
Distance worked (f/mo) 42 6.37 (4.40, 10.90) 95 8.40 (6.12, 11.56) 0.93 (0.85, 1.01) 0.081
Distance events (f/mo) 42 10.45 (7.50, 15.08) 95 11.75 (8.67, 15.56) 0.96 (0.90, 1.02) 0.194
Time between races (d) 34 38.86 (57.33, 78.47) 72 69.77 (42.96, 111.49) 0.99 (0.98, 1.00) 0.011
Time between works (d) 40 20.75 (11.58, 29.10) 93 15.83 (11.73, 21.27) 1.03 (1.00, 1.06) 0.025
Time between events (d) 40 14.29 (9.09, 19.05) 94 12.58 (9.73, 15.42) 1.02 (0.99, 1.06) 0.245
Active
Races per year 42 9.39 (5.93, 11.23) 95 7.47 (3.82, 10.43) 1.97 (1.09, 3.58)a 0.025
Works per year 42 29.87 (21.53, 39.60) 95 34.88 (27.71, 43.34) 0.62 (0.37, 1.05)a 0.078
Events per year 42 37.65 (32.53, 47.20) 95 42.69 (36.73, 48.88) 0.48 (0.19, 1.22)a 0.122
Distance raced (f/mo) 42 4.57 (3.19, 5.77) 95 3.70 (2.09, 5.81) 1.04 (0.93, 1.15) 0.503
Distance worked (f/mo) 42 9.98 (7.37, 12.18) 95 12.01 (8.99, 14.81) 0.89 (0.82, 0.97) 0.010
Distance events (f/mo) 42 14.71 (11.97, 16.85) 95 16.24 (13.46, 18.86) 0.90 (0.83, 0.97) 0.006
Time between races (d) 34 40.99 (32.62, 49.63) 72 46.66 (34.84, 76.90) 0.99 (0.97, 1.00) 0.061
Time between works (d) 40 12.60 (10.30, 16.87) 93 10.93 (9.00, 13.79) 1.06 (0.99, 1.14) 0.078
(Continued)
Frontiers in Veterinary Science | www.frontiersin.org 6 September 2018 | Volume 5 | Article 217
Hitchens et al. Predictors of Racehorse Catastrophic Injury
TABLE 3 | Continued
Cases (n = 42) Controls (n = 95) Odds ratio
(95% CI)
p-value
n Median (IQR) n Median (IQR)
Time between events (d) 40 10.16 (8.18, 11.45) 94 8.90 (7.90, 10.48) 1.16 (1.01, 1.32) 0.035
Exercise intensity (slope)
Slope at start 34 12.69 (8.78, 16.62) 86 12.79 (9.73, 15.83) 0.99 (0.91, 1.08) 0.839
Slope at date of death 39 12.71 (8.35, 16.42) 92 16.62 (13.37, 20.66) 0.87 (0.82, 0.92) <0.001
Slope after last layup 24 14.95 (8.93, 16.90) 60 16.84 (13.13, 19.24) 0.89 (0.81, 0.98) 0.014
Recent cumulative distances
1 month (f) 42 14 (7.5, 19.5) 95 19 (14, 24) 0.91 (0.87, 0.95) <0.001
2 months (f) 42 26 (15, 34) 95 33.5 (19.5, 40.5) 0.96 (0.94, 0.99) 0.008
4 months (f) 42 57.25 (27.5, 71.5) 95 53 (30, 72) 1.00 (0.99, 1.01) 0.781
6 months (f) 42 70.50 (31.5, 103) 95 65 (42, 102) 1.00 (0.99, 1.01) 0.666
8 months (f) 42 92.75 (45.5, 119) 95 75.5 (43, 114) 1.00 (1.00, 1.01) 0.570
10 months (f) 42 108.5 (48.5, 144) 95 86 (48, 125) 1.00 (1.00, 1.01) 0.668
12 months (f) 42 109.25 (48.5, 159.5) 95 88.5 (52, 149) 1.00 (1.00, 1.01) 0.796
Month 2 (f) 42 12.75 (4.5, 16.5) 95 13.5 (6.5, 18) 0.99 (0.94, 1.03) 0.557
Months 3 and 4 (f) 42 31 (12.5, 39) 95 20 (7, 35) 1.02 (1.00, 1.04) 0.044
Months 5 and 6 (f) 42 24 (1, 31.5) 95 10 (0, 32) 1.01 (1.00, 1.03) 0.145
Month 1 minus month 2 (f) 42 0.00 (-3, 7.5) 95 5.5 (2, 11) 0.91 (0.85, 0.97) 0.004
Median values presented are untransformed and based on the pooled unmatched data. d, day; mo, month; No., number; f, furlong. aOdds ratios determined from transformed data
using the log base 2.
High-Speed Exercise History
Univariable associations between CMI and high-speed exercise
history variables for Thoroughbred racehorses are presented in
Table 3. Case horses had greater career races and race distance,
higher frequency of races per year, less time between races,
greater time between works, lower work and event distances and
more time between events in periods without layup, and had
lower training and racing exercise intensity before death than
control horses.
Multivariable Analysis
In a multivariable model for TB cases and controls (Table 4),
horses that sustained CMI were more likely to have shown
signs of lameness <3 months prior to death. For TB CMI,
37.8% (14/37) of cases showed signs of lameness in the three
months prior to CMI compared to 23.3% (21/90) of controls. TB
cases that had previously raced (60.0%; 21/35) were less likely
to have been administered systemic medications compared to
controls (81.0%; 64/79); but unraced horses (57.1%; 4/7) were
more likely to have been administered systemic medications
compared to their controls (37.5%; 6/16) (interaction effect
p = 0.023). For horses that had previously raced, more
races per year over a horse’s race career was associated with
increased odds of CMI for a doubling of races. Additionally,
more races in months three and four combined, but fewer
cumulative furlongs worked and raced one month prior to
case death were associated with CMI. Due to the small sample
size, a multivariable model for the QH dataset could not be
fitted.
DISCUSSION
Modifiable risk factors for CMI related to lameness, medication,
surgery and exercise history of TB and QH racehorses in
California were investigated. TB cases were more likely to show
signs of lameness especially within three months prior to death,
and they were more likely to have been administered hyaluronic
acid injections compared to controls. A high proportion of both
cases and controls were administered medications, but unraced
TB cases were the most likely to have been administered systemic
medications. TB cases were more likely to have raced with greater
intensity during their whole career including 3–4 months prior,
but had eased off in the month preceding CMI. Significant
differences for lameness and for medication history were not
identified betweenQH cases and controls; but the sample size was
small. Associations with surgery history for both breeds were not
apparent.
TB cases were more likely to show signs of lameness within
the three months prior to their death. Fewer furlongs raced and
worked the two months prior to CMI for cases may have been an
indication that case horses were unable to maintain high exercise
intensity without developing lameness prior to a race. Reports
of the association between lameness and racing are conflicting.
Musculoskeletal conditions have been reported as the primary
reason for not starting in a race (40, 41), and of days lost to
training in the UK (41, 42), but in Germany the inability to train
at high-intensity did not predict racing soundness, race starts or
subsequent performance (43). Racehorses that have shown signs
of lameness in the months preceding their fatal injury are likely
to have a pre-existing condition. Such pre-existing conditions,
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TABLE 4 | Associations from multivariable logistic regression models, adjusting for
matching of cases and controls, between catastrophic musculoskeletal injury
sustained during racing or training and lameness, medication and surgery
histories of Thoroughbred racehorses in California, 2012–2013.
Odds ratio
(95% CI)
p-value
Main effects
Lameness 0–3 months 2.94 (1.05, 8.21) 0.040
Systemic medication 0.35 (0.10, 1.25) 0.105
Career
Raced
Previously raced Reference
Unraced 8.30 (0.45, 152.99) 0.155
Races per year 3.14 (1.39, 7.08)a 0.006
Recent cumulative distances
1 month (f) 0.84 (0.76, 0.93) 0.001
Months 3 and 4 (f) 1.07 (1.01, 1.13) 0.014
Interaction effect
Systemic medication # Raced
Systemic medication, unraced 28.69 (1.61, 512.88) 0.023
No., number; f, furlong. aOdds ratios determined from transformed data using the log
base 2.
stress fractures and/or pathology have been demonstrated in
a high proportion of racehorses at postmortem (7, 44–47).
We did not, however, have information on the severity of
lameness, or on more specific lameness timeframes closer to
the CMI occurring. This more detailed information may assist
in differentiating these high-risk horses from others more
readily.
A high proportion (73%) of all study horses were administered
medication. Difficulties arise in determining whether medication
is a risk factor for CMI due to such a high exposure amongst
both cases and controls. However, we did find that TB cases that
had previously raced were less likely to have been administered
systemic medications, likely due to the restrictions of medicating
close to race-day. Conversely, unraced case horses were more
likely to have been administered systemic medications, possibly
for the opposing reason. Although conducted more than
three decades ago, Dirikolu et al. (36) also observed a high
proportion of horses, in both injured and non-injured groups,
with detectable levels of the NSAIDs phenylbutazone (83%) and
flunixin (69%). Further, they found plasma concentrations of
these NSAIDs were greater in injured horses when compared
to a randomly selected horse in the same race (36). In this
present study, associations with specific medications were not
apparent, with the exception that cases that died as a result of a
training-related incident had more than five times greater odds
of being administered hyaluronic acid injections compared to
controls. Although we found no significant differences between
CMI cases and controls and use of corticosteroids, in an
Australian study, Whitton et al. (37) reported a higher incidence
of musculoskeletal injury (defined as a limb injury that resulted
in the horse not racing for at least 6 months, or being retired)
in horses administered local corticosteroid injections at any time
compared to those that were not injected. Further, in their study
horses administered two or more injections or with autologous
conditioned serum had the highest incidence of musculoskeletal
injury. The majority of musculoskeletal injuries (84%) occurred
within two months of the last local corticosteroid injection.
The addition of hyaluronic acid to corticosteroid injection did
not significantly decrease incidence of musculoskeletal injury
(37).
Thoroughbred cases had eased off racing one and two months
preceding CMI. A study piloted by Cohen et al. (33) showed
that horses that sustain musculoskeletal injuries during a race
tend to have accumulated significantly fewer furlongs over
the previous month or two months than horses that are not
injured in the same race. By contrast, a study by Estberg et al.
(17) found that horses that had accumulated more furlongs
in the two months before a race were more likely to suffer a
fatal injury during that race than horses that had accumulated
fewer furlongs. Cohen et al. (33) speculated that the differences
between their study in Kentucky and the study by Estberg
et al. (17) in California could be due to differences between the
populations, race surface, training or racing practices, or high-
speed variables. Though our study was also from California,
we showed similarities with that of Cohen et al. (33), and we
similarly hypothesize that the lack of recent exercise may have
been due to the development of pathology that limited the
cases capacity for high-intensity exercise; or because lack of
recent high-intensity exercise resulted in greater porosity and
decreased bone density, as has been demonstrated in studies
investigating fracture of the condyles of the third metacarpal
bone (48, 49).
There are limitations that should be considered when
interpreting the findings from this survey. The survey response
rate was 32%, with subsequent incomplete matching due to the
lower response of attending veterinarians of controls. Only large
effect sizes were detected because we had only 58% power to
detect an OR of 2.0, but 93% power to detect an OR of 3.0
at an alpha level of 5%. An estimated 92 cases, with complete
1:3 matching are required to detect an OR of 2.0 with power
of 80%, assuming a prevalence of exposure among controls
of 50%. The survey was initially planned to run for another
complete year which, at the observed response rate, would have
reached this target. Both missing information from completed
surveys, misreporting, or non-response may be a source of
bias. There is further potential risk of intentional censoring of
medication history, or medication being administered without
the knowledge or consent of the attending veterinarian. A
higher proportion of case veterinarians noted that the reason
for missing or unknown information was that the horse had
been claimed, shipped in or changed trainers in the previous
12 months (17% of cases compared to 9% controls). Ideally,
complete veterinary records of each horse would be the gold
standard for use in analysis, however until complete veterinary
records of all horses are required for regulatory purposes, this
approach is not feasible. To facilitate ongoing investigation of
risk factors, as well as being able to identify racehorses at
risk for injury, it is imperative that detailed veterinary records
accompany horses as they move between stables or training
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facilities. Lastly, questions regarding lameness could have been
more specific. Although signs of lameness within 3 months prior
to CMI was a significant risk factor, we do not know how
close to the point of CMI the horse was observed to be lame,
or indeed the severity of the lameness. It is also possible that
the horse may have been lame during a specified time period,
but that it was not attended to or reported to the veterinarian.
Future surveys should consider includingmore detailed lameness
questions.
Confirmation of the findings from this study, particularly
those related to medication history, will provide information
that can be used to aid in identification of horses at high risk
for catastrophic injury, and management factors that can be
modified to reduce the risk for all racehorses. Horses that have
been observed to be lame should be differentially diagnosed
where possible so that introduction to high-intensity exercise
is not attempted prematurely. Identification of lameness and/or
indicators of lameness should be pursued in future studies.
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